Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Rheumatoid arthritis

When TNF inhibitors fail in RA—weighing up the options

Nature Reviews Rheumatology volume 10, pages 262–264 (2014)Cite this article

Subjects

What is the best rheumatoid arthritis therapy after failure of a first anti-TNF drug? No consensus has been reached on whether to switch to rituximab or an alternative TNF inhibitor. New observational studies suggest that either course can be effective. But are more data needed?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Soliman, M. M. et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res. (Hoboken) 64, 1108–1115 (2012).

    CAS  Google Scholar 

  2. Gomez-Reino J. J. et al. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann. Rheum. Dis. 71, 382–385 (2012).

    Article  Google Scholar 

  3. Chatzidionysiou, K. & van Vollenhoven, R. F. Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. Scand. J. Rheumatol. 42, 190–195 (2013).

    Article  CAS  Google Scholar 

  4. Chatzidionysiou, K. et al. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-204714.

  5. Emery, P. et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203993.

  6. Finckh, A. et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann. Rheum. Dis. 69, 387–393 (2010).

    Article  CAS  Google Scholar 

  7. Chatzidionysiou, K. et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann. Rheum. Dis. 70, 1575–1580 (2011).

    Article  CAS  Google Scholar 

  8. Gomez-Reino, J. J. et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann. Rheum. Dis. 71, 1861–1864 (2012).

    Article  CAS  Google Scholar 

  9. Soliman, M. M. et al. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J. Rheumatol. 39, 240–246 (2012).

    Article  CAS  Google Scholar 

  10. Salliot, C. et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann. Rheum. Dis. 70, 266–271 (2011).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

L.S.-F. was supported in part by a EULAR Scientific Training Bursary.

Author information

Authors and Affiliations

  1. Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, the University of Manchester, Manchester Academic Health Science Centre, Room 2.800 Stopford Building, Oxford Road, Manchester, M13 9PT, UK

    Lucia Silva-Fernandez & Kimme Hyrich

Authors
  1. Lucia Silva-Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kimme Hyrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kimme Hyrich.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silva-Fernandez, L., Hyrich, K. When TNF inhibitors fail in RA—weighing up the options. Nat Rev Rheumatol 10, 262–264 (2014). https://doi.org/10.1038/nrrheum.2014.34

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2014.34

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing